AXL and non-small cell lung carcinoma: We found that in erlotinib-resistant NSCLC cell lines, knockdown of integrin β3 significantly reduced expression levels of AXL and nuclear YAP, while overexpression of YAP significantly rescued the decreased expression of AXL.